[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letter-eritrean-corporation-dba-first-choice-pipe-tobacco-702378-02272025":3,"fda-latest-sync-dates":30},{"id":4,"letter_id":5,"action_type":6,"firm_name":7,"fei_number":8,"issuing_office":9,"subject":10,"posted_date":11,"action_taken_date":12,"response_letter_date":8,"closeout_date":8,"case_status":13,"letter_url":14,"reference_number":15,"marcs_cms_no":16,"product_type":17,"delivery_method":18,"recipient_name":19,"recipient_title":8,"body_html":20,"body_text":21,"body_fetched_at":22,"medical_device_id":8,"raw":23,"created_at":28,"updated_at":29},957,"eritrean-corporation-dba-first-choice-pipe-tobacco-702378-02272025","Warning Letter","Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco",null,"Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","2025-04-15","2025-02-27","Issued","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feritrean-corporation-dba-first-choice-pipe-tobacco-702378-02272025","ER2501108","702378","Tobacco","VIA UPS and Electronic Mail","(b)(6)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv class=\"inset-column\">\n  \u003Cdl class=\"lcds-description-list--grid\">\n\n              \u003Cdt class=\"cell-1_1\">Delivery Method:\u003C\u002Fdt> \n        \u003Cdd class=\"cell-2_1\">VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt class=\"cell-1_2\">Reference #:\u003C\u002Fdt> \n        \u003Cdd class=\"cell-2_2\">ER2501108\u003C\u002Fdd>\n      \n              \u003Cdt class=\"cell-1_3\">Product:\u003C\u002Fdt> \n        \u003Cdd class=\"cell-2_3\">Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv class=\"row inset-column\">\n  \u003Cdiv class=\"col-xs-12 col-md-6\">\n    \u003Cdl class=\"\">\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv class=\"field field--name-field-recipient-name field--type-string field--label-above\">\n    \u003Cdiv class=\"field--label\">Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv class=\"field--item\">(b)(6)\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv class=\"field field--name-field-recipient-title field--type-string field--label-above\">\n    \u003Cdiv class=\"field--label\">Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv class=\"field--item\">Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp class=\"address\" translate=\"no\">\u003Cspan class=\"address-line1\">3526 C Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan class=\"locality\">Northeast Auburn\u003C\u002Fspan>, \u003Cspan class=\"administrative-area\">WA\u003C\u002Fspan> \u003Cspan class=\"postal-code\">98002\u003C\u002Fspan>\u003Cbr>\n\u003Cspan class=\"country\">United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\u003C!-- Loop this field. For FDA Office content type. Display the Other contact channel is a dd span with an icon-->\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan class=\"fa fa-envelope\" aria-hidden=\"true\">\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv class=\"col-xs-12 col-md-6\">\n    \u003Cdl class=\"\">\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp class=\"address\" translate=\"no\">\u003Cspan class=\"country\">United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl class=\"\"> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 27, 2025\u003C\u002Fp>\u003Cp class=\"text-align-center\">\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear\u003Cstrong> (b)(6)\u003C\u002Fstrong>,\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our records and determined that Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco (“Firm”) is a domestic importer and manufacturer of pipe tobacco for the purposes of section 919 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. § 387s) and subject to user fees in accordance with that provision. Section 919(b)(6) of the FD&C Act (21 U.S.C. § 387s(b)(6)) requires that each domestic importer and manufacturer of certain tobacco products, including pipe tobacco, remit payment of its user fee assessment by the last day of the applicable quarter.\u003C\u002Fp>\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Pay Assessed User Fees\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that all regulated tobacco products imported and manufactured by Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco are adulterated under section 902(4) of the FD&C Act (21 U.S.C. § 387b(4)) because your Firm has failed to pay assessed user fees as required by section 919 of the FD&C Act (21 U.S.C. § 387s). Specifically, based on our records, your Firm imports and manufactures tobacco products into the United States subject to user fees under section 919 of the FD&C Act, and your Firm was assessed user fees by FDA’s Office of Financial Management (OFM) on the dates indicated below. Section 919(b)(6) of the FD&C Act (21 U.S.C. § 387s(b)(6)) requires that payments of all assessments must be made by the last day of the applicable quarter. To date, FDA has not received payment from your Firm for the invoices enumerated in the table below.\u003C\u002Fp>\u003Cdiv class=\"table-responsive\">\u003Ctable class=\"table\">\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">\u003Cstrong>Fiscal Quarter\u002FYear of Assessment\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">\u003Cstrong>Assessment Invoice Date\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">\u003Cstrong>Assessment Due Date\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">2nd Quarter 2019\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">3\u002F1\u002F2019\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">3\u002F31\u002F2019\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">3rd Quarter 2019\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">6\u002F1\u002F2019\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">7\u002F1\u002F2019\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">3rd Quarter 2020\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">5\u002F31\u002F2020\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">6\u002F30\u002F2020\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">4th Quarter 2020\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">8\u002F31\u002F2020\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">9\u002F30\u002F2020\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">1st Quarter 2021\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">12\u002F1\u002F2020\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">12\u002F31\u002F2020\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">2nd Quarter 2021\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">3\u002F1\u002F2021\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">3\u002F31\u002F2021\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">1st Quarter 2022\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">12\u002F1\u002F2021\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">12\u002F31\u002F2021\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">1st Quarter 2023\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">12\u002F1\u002F2022\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">12\u002F31\u002F2022\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cp class=\"text-align-center\">3rd Quarter 2023\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">5\u002F31\u002F2023\u003C\u002Fp>\u003C\u002Ftd>\u003Ctd>\u003Cp class=\"text-align-center\">6\u002F30\u002F2023\u003C\u002Fp>\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>Because you have failed to pay user fees assessed pursuant to section 919 of the FD&C Act by the date specified in section 919, regulated tobacco products imported and manufactured by Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco are adulterated under section 902(4) of the FD&C Act (21 U.S.C. § 387b(4)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)), the introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated is a prohibited act.\u003C\u002Fp>\u003Cp>In addition, compliance with the requirements of the FD&C Act under section 910(a)(2)(A)(i) of the FD&C Act (21 U.S.C. § 387j(a)(2)(A)(i)) includes payment of assessed user fees as set forth in section 919 of the FD&C Act. Accordingly, FDA is unable to issue an order finding a new tobacco product described in a pending or future substantial equivalence (SE) Report -- other than for products marketed between February 15, 2007 and March 22, 2011, and for which an SE report was submitted by March 22, 2011— to be substantially equivalent to the predicate tobacco product until your Firm has paid its assessed fees in their entirety.\u003C\u002Fp>\u003Cp>Please note that entering a repayment plan for assessed user fees does not render a product compliant with the requirements of the FD&C Act. A firm in arrears, even if on a repayment plan, “fails to pay a user fee assessed to such manufacturer or importer pursuant to section 919 by the date specified in section 919 or by the 30th day after final agency action on a resolution of any dispute as to the amount of such fee,” (section 902(4) of the FD&C Act) and thus its products are adulterated.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance and your plan for maintaining compliance with the FD&C Act. Your response should include:\u003C\u002Fp>\u003Cp>1. Documentation showing that you have paid or have contacted OFM at userfees@fda.gov for information on how to pay your assessed user fees and set up a plan to pay those fees.\u003C\u002Fp>\u003Cp>2. Documentation to show the steps you have taken to prevent similar violations from occurring again in the future.\u003C\u002Fp>\u003Cp>3. If your firm’s planned corrections will occur over time, please include a timetable for implementation of those activities.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501108, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>FDA Center for Tobacco Products\u003Cbr>c\u002Fo Document Control Center\u003Cbr>Building 71, Room G335\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>or\u003C\u002Fp>\u003Cp>ctpcompliance@fda.hhs.gov\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact Kristina Peters, Office of Compliance and Enforcement, CTP, at (301) 796-4083 or kristina.peters@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>cc: Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco\u003Cbr>Attn: \u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003Cbr>6612 East Seltice Way\u003Cbr>Post Falls, Idaho 83854\u003C\u002Fp>\n\n\u003C!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->\n\u003C!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501108\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\n(b)(6)\n\nRecipient Title\n\nOwner\n\nEritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco\n\n3526 C Street\n\nNortheast Auburn, WA 98002\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 27, 2025\nWARNING LETTER\nDear (b)(6),\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our records and determined that Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco (“Firm”) is a domestic importer and manufacturer of pipe tobacco for the purposes of section 919 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. § 387s) and subject to user fees in accordance with that provision. Section 919(b)(6) of the FD&C Act (21 U.S.C. § 387s(b)(6)) requires that each domestic importer and manufacturer of certain tobacco products, including pipe tobacco, remit payment of its user fee assessment by the last day of the applicable quarter.\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\nFailure to Pay Assessed User Fees\nFDA has determined that all regulated tobacco products imported and manufactured by Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco are adulterated under section 902(4) of the FD&C Act (21 U.S.C. § 387b(4)) because your Firm has failed to pay assessed user fees as required by section 919 of the FD&C Act (21 U.S.C. § 387s). Specifically, based on our records, your Firm imports and manufactures tobacco products into the United States subject to user fees under section 919 of the FD&C Act, and your Firm was assessed user fees by FDA’s Office of Financial Management (OFM) on the dates indicated below. Section 919(b)(6) of the FD&C Act (21 U.S.C. § 387s(b)(6)) requires that payments of all assessments must be made by the last day of the applicable quarter. To date, FDA has not received payment from your Firm for the invoices enumerated in the table below.\nFiscal Quarter\u002FYear of Assessment\nAssessment Invoice Date\nAssessment Due Date\n\n2nd Quarter 2019\n3\u002F1\u002F2019\n3\u002F31\u002F2019\n\n3rd Quarter 2019\n6\u002F1\u002F2019\n7\u002F1\u002F2019\n\n3rd Quarter 2020\n5\u002F31\u002F2020\n6\u002F30\u002F2020\n\n4th Quarter 2020\n8\u002F31\u002F2020\n9\u002F30\u002F2020\n\n1st Quarter 2021\n12\u002F1\u002F2020\n12\u002F31\u002F2020\n\n2nd Quarter 2021\n3\u002F1\u002F2021\n3\u002F31\u002F2021\n\n1st Quarter 2022\n12\u002F1\u002F2021\n12\u002F31\u002F2021\n\n1st Quarter 2023\n12\u002F1\u002F2022\n12\u002F31\u002F2022\n\n3rd Quarter 2023\n5\u002F31\u002F2023\n6\u002F30\u002F2023\n\nBecause you have failed to pay user fees assessed pursuant to section 919 of the FD&C Act by the date specified in section 919, regulated tobacco products imported and manufactured by Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco are adulterated under section 902(4) of the FD&C Act (21 U.S.C. § 387b(4)).\nConclusion and Requested Actions\nUnder section 301(a) of the FD&C Act (21 U.S.C. § 331(a)), the introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated is a prohibited act.\nIn addition, compliance with the requirements of the FD&C Act under section 910(a)(2)(A)(i) of the FD&C Act (21 U.S.C. § 387j(a)(2)(A)(i)) includes payment of assessed user fees as set forth in section 919 of the FD&C Act. Accordingly, FDA is unable to issue an order finding a new tobacco product described in a pending or future substantial equivalence (SE) Report -- other than for products marketed between February 15, 2007 and March 22, 2011, and for which an SE report was submitted by March 22, 2011— to be substantially equivalent to the predicate tobacco product until your Firm has paid its assessed fees in their entirety.\nPlease note that entering a repayment plan for assessed user fees does not render a product compliant with the requirements of the FD&C Act. A firm in arrears, even if on a repayment plan, “fails to pay a user fee assessed to such manufacturer or importer pursuant to section 919 by the date specified in section 919 or by the 30th day after final agency action on a resolution of any dispute as to the amount of such fee,” (section 902(4) of the FD&C Act) and thus its products are adulterated.\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance and your plan for maintaining compliance with the FD&C Act. Your response should include:\n1. Documentation showing that you have paid or have contacted OFM at userfees@fda.gov for information on how to pay your assessed user fees and set up a plan to pay those fees.\n2. Documentation to show the steps you have taken to prevent similar violations from occurring again in the future.\n3. If your firm’s planned corrections will occur over time, please include a timetable for implementation of those activities.\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501108, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nor\nctpcompliance@fda.hhs.gov\nIf you have any questions about the content of this letter, please contact Kristina Peters, Office of Compliance and Enforcement, CTP, at (301) 796-4083 or kristina.peters@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\ncc: Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco\nAttn: (b)(6)\n6612 East Seltice Way\nPost Falls, Idaho 83854","2026-08-19T16:52:44.101+00:00",[24,25,26,9,10,27,27,27],"\u003Ctime datetime=\"2025-04-15T04:00:00Z\">04\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-27T05:00:00Z\">02\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feritrean-corporation-dba-first-choice-pipe-tobacco-702378-02272025\">Eritrean Corporation d\u002Fb\u002Fa First Choice Pipe Tobacco\u003C\u002Fa>","","2026-08-18T06:42:28.676509+00:00","2026-08-20T02:24:55.884391+00:00",{"510k":31,"classification":32,"enforcement":33,"event":34,"pma":35,"warning_letter":36},"2026-08-18T06:35:18.347+00:00","2026-08-18T05:52:53.75+00:00","2026-08-18T08:01:54.918+00:00","2026-08-19T02:58:35.995+00:00","2026-08-18T06:36:30.549+00:00","2026-08-20T03:28:02.95+00:00"]